24
total announcements
543322.BO · 15 min delayed
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has informed the stock exchanges about the details of Investors/Analyst meetings to be conducted on various dates in August and September 2026. The meetings will be held in virtual and in-person modes at various locations in Mumbai.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. The acquisition will enable Alivus to leverage its core portfolio selectively into advanced formulation development and expand its global customer base in the generic pharmaceutical segment.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced the acquisition of 76% stake in IQGEN-X Pharma Private Limited for INR 9.12 crores, subject to customary adjustments. The acquisition is expected to provide a wider spectrum for the company to offer a complete end-to-end solution to its customers in both API and CDMO space.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced an investors/analyst meeting on August 18-19, 2026, with various investment firms, including Green Lantern Capital, SIMPL, Burman Capital, and Karma Capital.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced the notice of its 15th Annual General Meeting (AGM) and e-voting information. The AGM will be held through video conferencing, and shareholders will be able to cast their votes on the proposed resolutions. The company has also confirmed the dispatch of the notice of AGM and the integrated annual report for the financial year 2025-26.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has submitted its Business Responsibility & Sustainability Report for FY 2025-26, as per SEBI regulations.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has submitted its Integrated Annual Report for FY 2025-26, as per Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report is available on the company's website and has been sent to shareholders through electronic mode.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced the notice of its 15th Annual General Meeting (AGM) for FY 2025-26, to be held on September 8, 2026. The meeting will be conducted through video conferencing or other audio-visual means. The company has also provided the facility for shareholders to exercise their right to vote on the resolutions proposed to be passed at the AGM by electronic means.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced an investor meet on August 12, 2026, to be attended by the company's representatives. The meeting will be held in Mumbai, and the schedule and mode may be subject to change due to exigencies.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd announces an investor/analyst meeting on August 12, 2026, in Mumbai, which may be subject to change due to exigencies.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd reported Q1 FY '27 results with revenue of INR640 crores, a 6.4% year-on-year growth, driven by strong non-GPL business growth of 26.5% year-on-year. The company expects healthy growth momentum in the non-GPL business to continue, supported by a robust product pipeline and sustained demand across all markets.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced a newspaper advertisement for its 15th Annual General Meeting (AGM) to be held on September 8, 2026, through video conferencing.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced the record date for its 15th Annual General Meeting and declared a final dividend of Rs. 5.00 per equity share for the financial year ended March 31, 2026.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced its 15th Annual General Meeting (AGM) to be held on September 8, 2026, through video conferencing. The company has also recommended a final dividend of Rs. 5.00 per equity share for the financial year ended March 31, 2026, subject to approval by shareholders.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has uploaded the audio recording of its Q1 FY2027 Earnings Call on its website.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has approved the allotment of 32,000 equity shares to eligible employees under the 'Employee Stock Option Scheme, 2021'. The paid-up share capital of the company has increased to Rs. 24,55,42,896.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has released its Q1 FY 2026-27 investor presentation, highlighting a positive start to the year with strong execution and accelerating traction in the non-GPL business. The company expects revenue growth of 10% - 12% in FY27, while sustaining EBITDA margins in the 30%–32% range.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd reported Q1FY27 results with revenue growth of 6.4% YoY, EBITDA growth of 29.1% YoY, and PAT growth of 31.8% YoY. The company achieved its highest-ever PAT margin of 25.0% and EBITDA margin of 36.6%. The company also announced plans for capacity expansion and pipeline development.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at Rs. 6,404.14 million, a decrease of 6.3% from the previous quarter. Net profit for the period was Rs. 1,600.76 million, with earnings per equity share at Rs. 13.04.
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at ₹6,404.14 crore and net profit for the period at ₹1,600.76 crore.